Anatara Lifesciences Q3 FY2024 Activities Report

Anatara Lifesciences Ltd (ASX: $ANR) has released its Q3 FY2024 Activities Report, highlighting significant progress in the pivotal GaRP-IBS (Irritable Bowel Syndrome) trial. The Company reported that patients can now formally register their interest to enroll in the second stage of the trial at 5 sites in Melbourne, Sydney, and Brisbane following the completion of the Ethics Approval process. Additionally, the appointment of Dr. Michael West as Chief Scientific Officer aims to strengthen the management team and address resources needed for refining product development and manufacturing.

Executive Commentary

The ongoing progress in the GaRP-IBS trial signifies a promising advancement in addressing the unmet need for an effective treatment for IBS. We anticipate strong interest in the trial, and the appointment of Dr. Michael West as Chief Scientific Officer reflects our commitment to enhancing our product development and manufacturing capabilities. We are also actively engaging with potential partners to deliver a new, safe, and effective treatment for IBS, and we remain dedicated to assessing opportunities in the human healthcare space as well as potential uses for animal health.

Summary of Q3 FY2024 Activities

Anatara Lifesciences has made significant strides in the pivotal GaRP-IBS trial, with patients now able to register for the second stage at multiple sites. The appointment of Dr. Michael West as Chief Scientific Officer further strengthens the Company's management team. The Q3 FY2024 cashflows indicate ongoing corporate and business development activities, and the Company is in the process of finalizing a fully subscribed placement with existing shareholders to raise further cash for its operations. Anatara Lifesciences remains committed to delivering innovative, evidence-based products for gastrointestinal health and is focused on building a pipeline of human gastrointestinal health products.